Next Article in Journal
Cysteine Mutations in the Ebolavirus Matrix Protein VP40 Promote Phosphatidylserine Binding by Increasing the Flexibility of a Lipid-Binding Loop
Next Article in Special Issue
An Update on Innate Immune Responses during SARS-CoV-2 Infection
Previous Article in Journal
Aerobic Conditions and Endogenous Reactive Oxygen Species Reduce the Production of Infectious MS2 Phage by Escherichia coli
Article

Dynamic Assay for Profiling Anti-SARS-CoV-2 Antibodies and Their ACE2/Spike RBD Neutralization Capacity

1
Department of Clinical Medicine, Trinity Translational Medicine Institute, School of Medicine, Trinity College Dublin, D08 W9RT Dublin, Ireland
2
Department of Immunology, St. James’s Hospital, D08 NHY1 Dublin, Ireland
3
Department of Immunology, School of Medicine, Trinity College Dublin, D02 R590 Dublin, Ireland
4
Department of Infectious Diseases, St James’s Hospital, D08 NHY1 Dublin, Ireland
5
Peak Proteins Ltd., Alderley Park, Mereside, Macclesfield SK10 4TG, UK
6
Department of Microbiology, Icahn School of Medicine, Mount Sinai, New York, NY 10029-5674, USA
7
Trinity Health Kidney Centre, Trinity Translational Medicine Institute, Trinity College Dublin, St. James’ Hospital Campus, D08 W9RT Dublin, Ireland
8
Department of Pharmacy, St James’s Hospital, D08 NHY1 Dublin, Ireland
*
Authors to whom correspondence should be addressed.
Both authors contributed equally to this work.
Academic Editors: Elmostafa Bahraoui and Remi Planes
Viruses 2021, 13(7), 1371; https://doi.org/10.3390/v13071371
Received: 11 June 2021 / Revised: 6 July 2021 / Accepted: 12 July 2021 / Published: 15 July 2021
(This article belongs to the Special Issue SARS-CoV-2 Innate and Adaptive Immune Responses)
Serological assays have been widely employed during the coronavirus disease 2019 (COVID-19) pandemic to measure antibody responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and to track seroconversion in populations. However, currently available assays do not allow determination of neutralization capacity within the assay protocol. Furthermore, commercial serology assays have a high buy-in cost that is inaccessible for many research groups. We have replicated the serological enzyme-linked immunosorbent assay for the detection of SARS-CoV-2 antibody isotypes, developed at the Icahn School of Medicine at Mount Sinai, New York. Additionally, we have modified the protocol to include a neutralization assay with only a minor modification to this protocol. We used this assay to screen local COVID-19 patient sera (n = 91) and pre-COVID-19 control sera (n = 103), and obtained approximate parity with approved commercial anti-nucleoprotein-based assays with these sera. Furthermore, data from our neutralization assay closely aligns with that generated using a spike-based pseudovirus infection model when a subset of patient sera was analyzed. View Full-Text
Keywords: antibody; enzyme-linked immunosorbent assay; neutralization; SARS-CoV-2; serology; pseudovirus infection model antibody; enzyme-linked immunosorbent assay; neutralization; SARS-CoV-2; serology; pseudovirus infection model
Show Figures

Graphical abstract

MDPI and ACS Style

Phelan, T.; Dunne, J.; Conlon, N.; Cheallaigh, C.N.; Abbott, W.M.; Faba-Rodriguez, R.; Amanat, F.; Krammer, F.; Little, M.A.; Hughes, G.; Bergin, C.; Kerr, C.; Sundaresan, S.; Long, A.; McCormack, W.; Brady, G. Dynamic Assay for Profiling Anti-SARS-CoV-2 Antibodies and Their ACE2/Spike RBD Neutralization Capacity. Viruses 2021, 13, 1371. https://doi.org/10.3390/v13071371

AMA Style

Phelan T, Dunne J, Conlon N, Cheallaigh CN, Abbott WM, Faba-Rodriguez R, Amanat F, Krammer F, Little MA, Hughes G, Bergin C, Kerr C, Sundaresan S, Long A, McCormack W, Brady G. Dynamic Assay for Profiling Anti-SARS-CoV-2 Antibodies and Their ACE2/Spike RBD Neutralization Capacity. Viruses. 2021; 13(7):1371. https://doi.org/10.3390/v13071371

Chicago/Turabian Style

Phelan, Thomas, Jean Dunne, Niall Conlon, Clíona N. Cheallaigh, W. M. Abbott, Raquel Faba-Rodriguez, Fatima Amanat, Florian Krammer, Mark A. Little, Gerry Hughes, Colm Bergin, Colm Kerr, Sudharshana Sundaresan, Aideen Long, William McCormack, and Gareth Brady. 2021. "Dynamic Assay for Profiling Anti-SARS-CoV-2 Antibodies and Their ACE2/Spike RBD Neutralization Capacity" Viruses 13, no. 7: 1371. https://doi.org/10.3390/v13071371

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop